Comerica Bank’s Revance Therapeutics, Inc. RVNC Stock Holding History

Comerica Bank’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-426	Closed	-$1.29K	–	3787
2024 Q4	$1.29K	Hold	426	–	–	﹤0.01%	3543
2024 Q3	$2.21K	Hold	426	–	–	﹤0.01%	3485
2024 Q2	$1.09K	Sell	426 -3,857	-90%	-$13.2K	﹤0.01%	3571
2024 Q1	$21.1K	Buy	4,283 +970	+29%	+$5.74K	﹤0.01%	3020
2023 Q4	$29.1K	Sell	3,313 -141	-4%	-$1.16K	﹤0.01%	2872
2023 Q3	$39.6K	Buy	+3,454	New	+$66.4K	﹤0.01%	2777

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Comerica Bank's RVNC Position: Q1 2025 in Review

Comerica Bank sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 426 shares — an estimated $1.29K sold.

Comerica Bank first reported a position in RVNC in Q3 2023 and held it in 6 quarters. The position peaked at $39.6K in Q3 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Comerica Bank reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Comerica Bank sold 426 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $1.29K.
Comerica Bank first reported a position in Revance Therapeutics, Inc. in Q3 2023 and held it in 6 quarters.
Comerica Bank's Revance Therapeutics, Inc. position peaked at $39.6K in Q3 2023.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Comerica Bank's 13F filing for Q1 2025, filed 14 May 2025.